ArticleBreast cancer (Tokyo, Japan)2026
Prognosis of patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative, 1-3 node-positive breast cancer meeting the high-risk criteria of the monarchE trial: a comparison between macrometastasis and micrometastasis.
Article in Breast cancer (Tokyo, Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe monarchE trial enrolled patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, high-risk early breast cancer (EBC). Although both macrometastasis and micrometastasis were eligible, the number of patients with only micrometastasis was not reported, leaving their prognosis uncertain. This study compared outcomes of patients with 1-3 positive axillary lymph nodes (pALNs), including those with only micrometastases and those with macrometastases, according to monarchE high-risk criteria.
methodsWe retrospectively reviewed 844 patients with HR-positive/HER2-negative/node-positive EBC from a prospectively maintained institutional database and classified them into four groups: Group 1, 1-3 pALNs (including macrometastasis) with grade 3 tumors or tumors ≥ 5 cm; Group 2, 1-3 pALNs (only micrometastasis) with grade 3 tumors or tumors ≥ 5 cm; Group 3, 1-3 pALNs (including macrometastasis) with grade < 3 tumors and tumors < 5 cm; and Group 4, 1-3 pALNs (only micrometastasis) with grade < 3 tumors and tumors < 5 cm. Invasive disease-free survival (IDFS) and distant relapse-free survival (DRFS) were analyzed using the Kaplan-Meier method and log-rank test. Univariable Cox models assessed associations between clinical factors and outcomes.
resultsGroup 2 showed outcomes comparable to Group 1 (5-year IDFS: 80.7% vs. 83.7%; DRFS: 89.5% vs. 87.9%). In univariate analysis, only tumor size-rather than Group 2 or histological grade-was prognostic for IDFS and DRFS. Sensitivity analyses restricted to patients undergoing axillary lymph node dissection yielded consistent results.
conclusionsAmong HR-positive/HER2-negative EBC, high-risk patients with only micrometastasis demonstrated prognoses similar to those with macrometastasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.